Bayer has announced that the HSE has granted hospital pricing approval for EYLEA® 8mg for eligible adult patients with wet age-related macular degeneration and diabetic macular oedema in Ireland.
Stakeholders at the AXIS Patient Access Conference in Dublin heard that Ireland must agree a clear operational roadmap to meet its 180-day reimbursement decision target.
